Hansa Biopharma AB (publ) (STO:HNSA)
Sweden
· Delayed Price · Currency is SEK 27.48
+0.08 (0.29%)
May 6, 2025, 9:59 AM CET
Hansa Biopharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 181.68 | 171.32 | 134.09 | 154.53 | 33.88 | 6.1 | Upgrade
|
Revenue Growth (YoY) | 9.53% | 27.76% | -13.22% | 356.12% | 455.56% | 81.27% | Upgrade
|
Cost of Revenue | 85.93 | 83.55 | 63.14 | 38.48 | 15.43 | 1 | Upgrade
|
Gross Profit | 95.76 | 87.76 | 70.95 | 116.05 | 18.45 | 5.1 | Upgrade
|
Selling, General & Admin | 329.01 | 344.27 | 450.49 | 337.86 | 327.27 | 202.99 | Upgrade
|
Research & Development | 337.02 | 375.72 | 411.33 | 346.24 | 230.76 | 227.19 | Upgrade
|
Other Operating Expenses | -4.61 | -0.59 | 0.29 | 8.06 | - | - | Upgrade
|
Operating Expenses | 661.42 | 719.4 | 862.11 | 692.17 | 558.03 | 430.18 | Upgrade
|
Operating Income | -565.66 | -631.64 | -791.16 | -576.12 | -539.58 | -425.08 | Upgrade
|
Interest Expense | -99.2 | -134.08 | -105.52 | -43.67 | -0.69 | -0.26 | Upgrade
|
Interest & Investment Income | 101.76 | 20.83 | 28.06 | 8.83 | 0.07 | 0.39 | Upgrade
|
Currency Exchange Gain (Loss) | -71.98 | -71.98 | 37.81 | 5.95 | -7.4 | 2.27 | Upgrade
|
Other Non Operating Income (Expenses) | 12.65 | 12.65 | - | -4.97 | -0.53 | 1.78 | Upgrade
|
EBT Excluding Unusual Items | -622.43 | -804.21 | -830.81 | -609.98 | -548.13 | -420.89 | Upgrade
|
Pretax Income | -622.43 | -804.21 | -830.81 | -609.98 | -548.13 | -420.89 | Upgrade
|
Income Tax Expense | 3.31 | 3.03 | 0.91 | 1.16 | 0.15 | -0.04 | Upgrade
|
Net Income | -625.74 | -807.24 | -831.72 | -611.13 | -548.28 | -420.85 | Upgrade
|
Net Income to Common | -625.74 | -807.24 | -831.72 | -611.13 | -548.28 | -420.85 | Upgrade
|
Shares Outstanding (Basic) | 67 | 63 | 53 | 45 | 44 | 42 | Upgrade
|
Shares Outstanding (Diluted) | 67 | 63 | 53 | 45 | 44 | 42 | Upgrade
|
Shares Change (YoY) | 26.66% | 19.59% | 16.95% | 1.01% | 5.45% | 5.39% | Upgrade
|
EPS (Basic) | -9.39 | -12.85 | -15.83 | -13.60 | -12.33 | -9.98 | Upgrade
|
EPS (Diluted) | -9.39 | -12.85 | -15.83 | -13.60 | -12.33 | -9.98 | Upgrade
|
Free Cash Flow | -638.24 | -675 | -755.94 | -506.06 | -483.57 | -290.57 | Upgrade
|
Free Cash Flow Per Share | -9.58 | -10.74 | -14.39 | -11.27 | -10.87 | -6.89 | Upgrade
|
Gross Margin | 52.71% | 51.23% | 52.91% | 75.10% | 54.47% | 83.65% | Upgrade
|
Operating Margin | -311.34% | -368.70% | -590.00% | -372.83% | -1592.71% | -6970.76% | Upgrade
|
Profit Margin | -344.41% | -471.20% | -620.25% | -395.49% | -1618.40% | -6901.49% | Upgrade
|
Free Cash Flow Margin | -351.29% | -394.01% | -563.74% | -327.50% | -1427.38% | -4764.97% | Upgrade
|
EBITDA | -563.18 | -629.08 | -788.33 | -573.71 | -538.06 | -422.29 | Upgrade
|
D&A For EBITDA | 2.48 | 2.55 | 2.83 | 2.41 | 1.52 | 2.79 | Upgrade
|
EBIT | -565.66 | -631.64 | -791.16 | -576.12 | -539.58 | -425.08 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.